Gómez NDA, Solís PCC, Delgado CMM, Villa GFI, Trejo MJJ, Peña OS

Language: Spanish
References: 18
Page: 126-130
PDF size: 150.90 Kb.

ABSTRACT

Objective: To determine if mirtazapina is useful to reduce the surgery stress in our patients.
Material and methods: It was an observational, longitudinal, prospective comparative and open study. We include 100 patients (50 men and 50 females), their age range was from 18 to 70 years-old with ASA classification in I and II. The patients were divided in two groups. In the first group, all patients received 30 mg p.o. of mirtazapina the night before surgery. In all patients there were evaluated their blood pressure, respiratory and cardiac rates, as well as saturation of arterial oxygen. Both groups were submitted to IDARE test in the night and in the morning.
Results: In all patients submitted to study there was little difference in haemodynamic effort in both groups. Secondary IDARE test showed a significative difference in both groups (p = ‹ 0.001).
Conclusions: It was observed that mirtazapina was effective as anaesthesia premedication to reduce anxiety in surgery proceedings by diminishing stress before being in surgery room.

REFERENCES

1. Kroll W, Gassmayr SE, Pre-operative anxiety, stress, and pre-medication. Baillieres Clin Anaesthesiol 1998;12(33):485-49.

2. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum Psychopharmacol 1995;10 (Suppl. 2):S83-96.

3. Delbressine LPC. Pharmacokinetics and relevance for choice. Eur Neuropsychopharmacol 1996;6(Suppl. 4):S4-64.

4. Delbressine LPC, Vos RME. The Clinical relevance of preclinical data: Mirtazapine, a model compound. J Clin Psychopharmacol 1997;17(Suppl. 2):S29-33.

5. Data on file, NV Organon, Oss, The Netherlands.

6. De Graaf J, Delbressine LPC. Contributions of the enantiomers of Org 3770 and its demethyl metabolite to its neuropharmacological profile in rats. Trends in Drug Research, 7th Noordwijkerhout-Camerino Symposium,1989:69.

7. Murdoch DL, Ashgar J, Ankier SI, et al. Influence of hepatic impairment on the pharmacokinetic of single dose of mirtazapine in elderly subjects. Br J Clin Pharmacol 1993;35:76.

8. Bengtsson F, Hoglund P, Timmer C, et al. Mirtazapine oral single dose kinetics in patients with different degrees of renal failure. Hum Psychopharmacol Clin Exp 1998;13(5):257-365.

9. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000;38(6):461-74.

10. Thase ME, Kupfer DJ. Current status of EEG sleep in the assessment and treatment of depression. In: Burrows GD, Werry JS (eds). Advances in human psychopharmacology. Greenwich, CT: JAI Press, 1987;4:93-148.

11. Akiskal HS. Mood disorders: Clinical features. In: Kaplan HI, Sadock BJ (eds). Comprehensive textbook of psychiatry. Baltimore, MD: Williams and Wilkins 1989:1123-52.

12. Ruigt GS, Kemp B, Groenhout CM, et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990,38(6):551-4.

13. Winokur A, Sateia MJ, Hayes JB, et al. Acute effects of mirtazapine on sleep contiunity and sleep architecture in depressed patients: A pilot study. Biol Psychiatry 2000;48(1):75-8.

14. Schittecatte M, Dumont F, Machowski R, et al. Effect of mirtazapine on sleep polygraphic variables in major depression. APA Annual Meeting, 2000:95.

15. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60(Suppl.17):28-31.

16. Da Roza Davis JM, Sharpley AL, Solomon RA, et al. Sleep and 5-HT2 receptor sensitivity in recovered depressed patients. J Affect Disord 1992;24(3):177-81.

17. Montgomery SA. Safety of mirtazapine: A review. Int Clin Psychopharmacol 1995;10(Suppl. 4):37-45.

18. Robles R, Varela R, Jurado S y Páez F. Versión mexicana del inventario de ansiedad de Beck: Propiedades psicométricas. Revista Mexicana de Psicología 2001;18(2):211-8.